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OBJECTIVE—Overweight and obese individuals are encouraged to lose 5–10% of their body
weight to improve cardiovascular disease (CVD) risk, but data supporting this recommendation
are limited, particularly for individuals with type 2 diabetes.
RESEARCH DESIGN AND METHODS—We conducted an observational analysis of
participants in the Look AHEAD (Action For Health in Diabetes) study (n = 5,145, 40.5% male,
37% from ethnic/racial minorities) and examined the association between the magnitude of
weight loss and changes in CVD risk factors at 1 year and the odds of meeting predeﬁned criteria
for clinically signiﬁcant improvements in risk factors in individuals with type 2 diabetes.
RESULTS—The magnitude of weight loss at 1 year was strongly (P , 0.0001) associated with
improvementsinglycemia,bloodpressure,tryiglycerides,andHDLcholesterolbutnotwithLDL
cholesterol (P = 0.79). Compared with weight-stable participants, those who lost 5 to ,10%
([means6SD]7.2562.1kg)oftheirbodyweighthadincreasedoddsofachievinga0.5%point
reduction inHbA1c(oddsratio3.52 [95%CI 2.81–4.40]),a5-mmHgdecrease indiastolic blood
pressure(1.48[1.20–1.82]),a5-mmHgdecreaseinsystolicbloodpressure(1.56[1.27–1.91]),a
5mg/dLincreaseinHDLcholesterol(1.69[1.37–2.07]),anda40mg/dLdecreaseintriglycerides
(2.20 [1.71–2.83]). The odds of clinically signiﬁcant improvements in most risk factors were
even greater in those who lost 10–15% of their body weight.
CONCLUSIONS—Modest weight losses of 5 to ,10% were associated with signiﬁcant
improvements in CVD risk factors at 1 year, but larger weight losses had greater beneﬁts.
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O
verweightandobeseindividualsare
frequently encouraged to lose 5–
10% of their weight and are told
that weight losses of that magnitude will
help improve their cardiovascular disease
(CVD) risk factors. For example, the
CentersforDiseaseControlandPrevention
website (www.cdc.gov/healthyweight/
losing_weight/index.html) states, “The
good news is that no matter what your
weight loss goal is, even a modest weight
loss, such as 5 to 10% of your total body
weight, is likely to produce health ben-
eﬁt s ,s u c ha si m p r o v e m e n t si nb l o o d
pressure, blood cholesterol, and blood
sugars.” The beneﬁts of modest weight
lossalsoarenotedbytheSurgeonGeneral
(www.surgeongeneral.gov/), the Insti-
tutes of Medicine (1), and the National
Institutes of Health (e.g., www.nhlbi
.nih.gov/ and www2.niddk.nih.gov/),
with citations to a variety of reviews of
the literature (2–4) and meta-analyses
(5). For example, the statement from the
Centers for Disease Control and Preven-
tion website cites a review by Blackburn
(6) for the beneﬁts of 5% weight loss and
the National Heart, Lung, and Blood In-
stitute Clinical Guidelines (7) as the ref-
erence for the beneﬁt of a 10% weight
loss. However, the studies included in
these reviews often had limited sample
sizes, focused onnondiabeticindividuals,
and typically presented only average
weight loss and the average reduction in
risk factors, which did not allow a careful
analysis of the association between speciﬁc
magnitudes of weight loss and consequent
improvements in CVD risk factors.
Look AHEAD (Action for Health in
Diabetes) provides a unique opportunity
to carefully assess the effects of modest
weight loss on CVD risk factors in indi-
viduals with type 2 diabetes, a population
at high risk for CVD. Look AHEAD is a
multicenter, randomized clinical trial ex-
amining the long-term effects of lifestyle
interventions on cardiovascular morbid-
ity and mortality in 5,145 overweight or
obese participants with type 2 diabetes
who were randomly assigned to intensive
lifestyleintervention(ILI)ortousualcare,
referred to as diabetes support and edu-
cation (DSE) (8,9). Differences between
ILI and DSE at 1 year have been reported
previously (9). In this article, we exam-
inetheassociationsbetweenthemagnitude
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ORIGINAL ARTICLEof weight loss and the degree of improve-
ment in glycemic control, blood pressure,
and lipid levels at 1 year in the full cohort.
We also determine the average risk factor
changeandtheoddsofmeetingpredeﬁned
criteria for clinically signiﬁcant improve-
ment in risk factors that are associated
with speciﬁc categories of weight change.
These analyses provide important data to
address the recommendations regarding
modest weight loss.
RESEARCH DESIGN AND
METHODS—Look AHEAD partici-
pants were recruited at 16 sites through-
out the U.S. The goal was to recruit
approximately equal numbers of men
and women and at least 33% from racial
and ethnic minorities (8). Primary eligi-
bility criteria included being aged 45–76
years (later increased to age 55–76 years);
having a BMI $25 kg/m2 ($27 kg/m
2 if
treated with insulin), systolic and dia-
stolic blood pressure (SBP and DBP)
,160/100 mmHg (with or without anti-
hypertensive drugs), and triglycerides
,600 mg/dL (with or without drugs for
dyslipidemia); and successful completion
of a valid maximal-graded exercise test. A
detailed ﬂowchart of the number of sub-
jects screened and reasons for ineligibility
has been published previously (9). All
participants signed consent forms that
were approved by their local institutional
review boards.
Interventions
Participants were randomly assigned by
clinic to either the ILI or DSE groups. The
interventions have been described in de-
tail (10). Participants in the ILI group had
the goal of losing 10% of their body
weight, to be accomplished by decreasing
caloric intake and increasing physical ac-
tivity. The ILI group was seen weekly for
6 months andthen threetimesper month
during months 7–12 and was provided
with a structured behavioral weight-
control intervention. ILI group partici-
pants were prescribed a calorie goal of
1,200–1,800 kcal/day depending on ini-
tialbodyweight,with30%ofkcalfromfat,
and the use of meal-replacement products.
Physical activity was gradually increased
to a goal of 175 min/week of moderate-
intensityactivities.TheDSEgroupattended
three meetings over the year and focused
on diet, activity, and social support.
Assessments
Participants were assessed at baseline and
1 year by certiﬁed staff members who
were blinded to the intervention assign-
ments.Weightandheightweremeasured
in duplicate using a digital scale and
stadiometer.Seatedbloodpressurewasmea-
sured in duplicate after a 5-min rest using
an automated device. Blood samples were
obtained after a fast of at least 12 h and
analyzed by the central biochemistry
laboratory (Northwest Lipid Research
Laboratories, University of Washington,
Seattle, WA) using standardized labora-
tory procedures for measuring HbA1c,
total cholesterol, HDL cholesterol, and
triglycerides. LDL cholesterol was esti-
mated using the Friedewald Equation
(11).
Medication use was determined by
having participants bring all prescription
medicines to the annual visit. Changes in
medicationsduringthetrialweremadeby
the participant’s own physician, except
for temporary changes in glycemic medi-
cation during periods of intensive weight
loss, which were made by Look AHEAD
physicians,followingastandardizedalgo-
rithm.
Statistical analyses
Analyses were performed using SAS ver-
sion9.2(SAS,Cary,NC).Thetype Ierror
rate was ﬁxed at 0.05. Normality of the
outcome variables (i.e., changes in CVD
risk factors) was examined before the
ﬁt of multiple linear regression models.
Spearman correlation coefﬁcients were
used to assess the bivariate associations
between weight loss and change in CVD
risk factors, both overall and stratiﬁed by
subgroups deﬁned by sex, intervention
group assignment, and medication use.
The primary analyses in this article
examined the relationships between cat-
egoriesofweightlossandchangesinCVD
risk factors. Participants were divided
into the following categories based on
their weight changes from baseline to
1year:gained.2%;remainedweightsta-
ble (62%); lost $2t o,5%; lost $5t o
,10%;lost$10to,15%;orlost$15%.
These categories were selected to allow us
to examine the clinical recommendation
to lose 5–10% of body weight, to isolate
those who had gained weight from a
weight-stable reference group, and to
determine whether weight changes of
.10% had even greater beneﬁts. Partici-
pants from both the ILI and DSE groups
were pooled for these analyses, with co-
variate adjustment for the main effect of
intervention group assignment. All anal-
yses also adjusted for age, sex, baseline
level of the outcome variables, baseline
weight,andrace/ethnicity.Separatelinear
regression models were ﬁt for changes
in SBP, DBP, glucose, HbA1c,H D La n d
LDL cholesterol, and triglycerides. Log
transformationwasappliedtotriglyceride
measures, with change scores calculated
onthelogscale.Becauseresultsweresim-
ilartothoseanalyzedontheoriginalscale,
we presented results for change in trigly-
cerideswithoutthe logtransformation.In
initial analyses we examined the interac-
tion effects between intervention group
assignment, sex, age, baseline weight,
race/ethnicity, and weight loss in associa-
tion with CVD risk factor changes. Least
square means were plotted to illustrate
signiﬁcant interaction effects. Although
some signiﬁcant interaction effects were
detected, in all cases the direction and
strength of the associations remained
consistent across subgroups, and thus
we focused primarily on the associations
for the full sample (i.e., interaction effects
were not included in the ﬁnal multiple
linear regression models).
Separate logistic regression models
were ﬁt to examine the effect of weight
loss on the odds of meeting predeﬁned
criteria indicating clinical meaningful im-
provement in CVD risk factors, deﬁned
as follows: 5 mmHg decrease in SBP or
DBP; a 20 mg/dL decrease in fasting glu-
cose; a 0.5% point decrease in HbA1c;a
5 mg/dL increase in HDL cholesterol; a
10 mg/dL decrease in LDL cholesterol;
and a 40 mg/dL decrease in triglycerides.
Estimatesofoddsratiosinreferencetothe
weight-stablegroupwerepresentedalong
with 95% CIs.
RESULTS
Changes in weight and CVD risk
Table1presentsthebaselinecharacteristics
of 5,145 participants in Look AHEAD.
Approximately 60% of the participants
were women, and 37% were from ethnic
or racial minority groups. Participants
were an average age of 58.7 6 6.8 years
and weighed 100.7 6 19.3 kg at study
entry.
Table 2 indicates the sample size
available for each measure at baseline
and 1 year, the baseline level of the risk
factors, and the mean changes in weight
and CVD risk factors at 1 year. In addi-
tion, Table 2 shows the magnitude of the
association between weight loss and
changes in risk factors. Weight changes
weresigniﬁcantlycorrelatedwithchanges
in glycemic control, blood pressure, HDL
cholesterol, and triglycerides; the greater
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Weight loss and improvement in cardiovascular riskthe weight change, the greater the im-
provements in each risk factor in the full
cohort and within the ILI and DSE group
separately.Weightlosswasnotassociated
with improvements in LDL cholesterol.
When the analysis was restricted to those
not on lipid medications, the correlation
between weight loss and change in LDL
cholesterol was signiﬁcant but weak (r =
0.06, P = 0.01).
Categorical changes in weight
To better describe the associations be-
tween weight change and improvements
in CVD risk factors, Look AHEAD partic-
ipants were categorized by their percent
weightchangesovertheﬁrst year. Table1
shows the number of participants who
gained .2% over this interval; remained
weight stable (62%); or lost $2t o,5%,
$5t o,10%, $10 to ,15%, or $15%.
The average weight changes (means 6
SD) were +4.73 6 3.0 kg for weight
gain; 20.11 6 1.16 kg for remaining
weight stable; and 23.48 6 1.11,
27.25 6 2.07, 212.13 6 2.83, and
221.25 6 7.05 kg for each increasing
weight loss category, respectively. Be-
cause ILI participants had a weight loss
(means 6 SD) of 8.7 6 7.6 kg compared
with 0.8 6 5.0 kg in the DSE group (P ,
0.0001), it was expected that participants
in the ILI group would be overrepre-
sented in the higher weight change cate-
gories. The weight change categories also
differed in their demographic character-
istics(Table1)andinthepercentagefrom
each category who stopped or started
medications (see the Supplementary Ma-
terials).
Figure 1 shows the least square mean
changes for each of the risk factors across
thesixweightchangecategories,adjusted
for age, sex, race, treatment group assign-
ment, baseline weight, and baseline level
of the risk factor. A strong graded asso-
ciation was seen for changes in glucose,
HbA1c, SBP, DBP, triglycerides, and HDL
cholesterol (all P values ,0.0001). Each
higher category of weight loss was associ-
ated with greater improvements in the
risk factor. In contrast, the magnitude of
improvement in LDL cholesterol did not
differacrosstheweightcategories,evenin
those not using lipid-lowering medica-
tions at baseline and 1 year. There were
no signiﬁcant interactions between base-
line weight and weight change categories,
except for HDL categories (P , 0.0002),
for which the slope of the association
Table 1—Baseline characteristics by weight change category
Total sample Gained .2%
Stable
Gained #2
or lost ,2%
Lost $2
to ,5%
Lost $5
to ,10%
Lost $10
to ,15% Lost $15% P
n 5,145 683 1,289 914 1,000 601 412
ILI group 50.1 (2,570) 12.6 (86) 21.2 (273) 47.4 (433) 74.9 (749) 90.9 (546) 94.2 (388) ,0.0001*
Male 40.5 (2,082) 35.9 (245) 43.0 (554) 39.2 (358) 38.7 (387) 41.4 (249) 47.6 (196) 0.0311*
Ethnicity 0.1106*
African American 15.6 (804) 15.7 (107) 17.1 (220) 17.8 (163) 17.2 (172) 11.8 (71) 7.0 (29)
American Indian 5.0 (258) 6.3 (43) 6.6 (85) 6.0 (55) 5.1 (51) 3.0 (18) 0.2 (1)
Hispanic 13.2 (680) 13.9 (95) 11.4 (147) 14.9 (136) 12.2 (122) 15.2 (91) 9.2 (38)
White 63.2 (3,253) 60.3 (412) 61.8 (797) 58.1 (531) 62.7 (627) 67.7 (406) 81.6 (336)
Asian/PaciﬁcI s l a n d e r /
other/mixed 2.9 (149) 3.8 (26) 3.1 (40) 3.2 (29) 2.8 (28) 2.3 (14) 1.9 (8)
Age 58.7 6 6.8 57.9 6 6.9 58.6 6 6.9 58.9 6 6.7 58.7 6 6.8 59.6 6 7.0 58.8 6 6.7 0.0009†
Height (cm) 167.2 6 9.7 166.1 6 9.7 167.9 6 9.9 167.0 6 9.8 167.0 6 9.5 167.1 6 9.8 168.7 6 9.7 0.0001†
Baseline BMI (kg/m
2)3 6 . 0 6 5.9 36.3 6 5.8 35.8 6 5.9 35.8 6 6.0 35.8 6 6.1 35.7 6 5.9 36.7 6 5.6 0.0028†
Baseline weight (kg) 100.7 6 19.3 100.1 6 18.1 101.0 6 19.0 100.1 6 19.5 100.2 6 20.3 99.8 6 18.7 104.7 6 19.1 ,0.0001†
Data are % (n)o rm e a n s6 SD. *P value for the Mantel-Haenszel x
2 test for trend. †P value for the Kruskal-Wallis test.
Table 2—Changes in CVD risk factors and association with percentage weight change for the Look AHEAD cohort
Baseline Change from baseline to year 1
Spearman correlation of association
with percentage weight loss
n Mean 6 SD n Mean 6 SD
Total
cohort
ILI
subjects
DSE
subjects
Weight (kg) 5,145 100.71 6 19.26 4,899 24.77 6 7.57*
SBP (mmHg) 5,082 128.84 6 17.17 4,837 24.76 6 17.05* 0.20* 0.19* 0.14*
DBP (mmHg) 5,082 70.15 6 9.57 4,837 22.40 6 8.62* 0.12* 0.13* 0.08*
Glucose 4,999 153.19 6 45.66 4,603 214.32 6 46.08* 0.27* 0.21* 0.14*
HbA1c (%) 4,999 7.28 6 1.17 4,606 20.39 6 1.02* 0.34* 0.24* 0.16*
HDL cholesterol (mg/dL) 4,999 43.48 6 11.83 4,603 2.39 6 6.97* 20.23* 20.26* 20.08*
LDL cholesterol (mg/dL) 4,998 112.31 6 32.24 4,602 25.47 6 28.63* 20.004 0.0008 20.02
Trigylcerides (mg/dL)† 4,999 153 (108–219) 4,603 212.0 (252 to 21)* 0.26* 0.31* 0.16*
*P,0.0001.†Forchange intriglycerides,dataaremedian(interquartile range).The signed-rank testwasusedtotestwhether thechangefrombaselinetoyear1was
different from 0.
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Wing and Associatesbetween weight change category and
change in HDL cholesterol was steepest
in those who weighed least at baseline.
Clinically signiﬁcant improvements
in CVD risk
The odds of having a clinically mean-
ingful improvement in risk factors also
were strongly related to the magnitude of
weightlossachieved(Table3).Compared
with those who remained weight stable,
no differences were observed for those
who gained weight. However, those who
lost 2–5% of their body weight had
increased odds of having signiﬁcant
improvements in SBP (odds ratio 1.24
[95% CI 1.02–1.50]), glucose (1.75
[1.40–2.19]), HbA1c (1.80 [1.44–2.24]),
and triglycerides (1.46 [1.14–1.87]), and
those who lost 5 to ,10% of their body
weight had increased odds of signiﬁcant
improvement in all risk factors. Results
remained similar after adjusting for start-
ing or stopping medications. The odds
of clinically signiﬁcant improvements in
risk factors were increased further with
greater weight losses, such that those
who lost 5–10% had greater odds of im-
provements than those who lost 2–5%,
and those who lost 10–15% had greater
odds of improvement than those who lost
5–10% (see the Supplemental Materials).
CONCLUSIONS—These results pro-
vide empirical support for the assertion
that modest weight losses of 5–10% of
initial weight are sufﬁcient to produce
signiﬁcant, clinically relevant improve-
ments in CVD risk factors in overweight
and obese patients with type 2 diabetes.
However, greater weight losses were as-
sociated with greater improvements in
risk factors. The magnitude of weight
loss at 1 year was highly related to the
improvements in blood pressure, glyce-
mic control, and lipids, with the notable
exception of LDL cholesterol.
Despite the fact that the ILI and the
DSE groups differed greatly in their av-
erage weight losses, positive associations
were seen between weight change and
improvements in risk factors within each
group separately. This ﬁnding suggests
that the degree of association between
weight change and improved risk factors
is relatively constant across a wide range
of weight losses. There also was no evi-
dence that a patient’sw e i g h ta tb a s e l i n e
affected the amount of improvement that
occurred with a given percentage change
in body weight, except for HDL choles-
terol, for which the magnitude of weight
loss had the greatest effect in the least
overweight participants.
The strongest associations between
changes in weight and risk factors were
seen for measures of glycemic control,
and clinically signiﬁcant improvements
were observed with just a 2 to ,5% re-
duction in initial weight. This ﬁnding
conﬁrmsalargenumberofpreviousstud-
ies indicating that modest weight losses
markedly improve glycemic control
(12). The fact that all participants in this
study had type 2 diabetes, whereas only
some had hypertension or hyperlipid-
emia, may be related to this ﬁnding. On
the other hand, the fact that caloric restric-
tion, independent of weight loss, improves
glycemic control (13,14) may suggest a
heightenedresponsivenessofthisriskfactor
to caloric imbalance and weight changes.
In contrast, we observed weaker as-
sociations between weight loss and LDL
cholesterol changes, even among partic-
ipants not using lipid medications at
either baseline or 1 year. Moreover, al-
though the odds of achieving a 10 mg/dL
Figure 1—Change in risk factors by weight loss categories for the Look AHEAD cohort. Data in
all ﬁgures are presented as least square means and 95% CIs adjusted for clinical sites, age, sex,
race/ethnicity, baseline weight, baseline measurement of the outcome variable, and treatment
group assignment.
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Weight loss and improvement in cardiovascular riskimprovement in LDL cholesterol were
signiﬁcantlyincreasedbya5–10%weight
loss relative to remaining weight stable,
the effects were not consistent across
greater weight loss categories, and even
weight losses of $15% of body weight
had modest effects on LDL cholesterol.
Although a meta-analysis (15) of studies
assessingtheeffectofweightlossonlipids
over at leasta2-yearfollow-upconcluded
that there was a positive linear relation-
ship between weight loss and improve-
ments in both total and LDL cholesterol,
some studies (14,16,17) have not con-
ﬁrmed this. Wadden et al. (16) reported
markedimprovementsinLDLcholesterol
during a period of caloric restriction, but
these improvements were not maintained
when calorie intake was increased, even
though weight losses were maintained.
Likewise, in the Swedish Obese Subjects
Study (17), mean weight losses of 20 kg
at 2yearsachieved throughgastricbypass
surgery were associated with nonsigniﬁ-
cant reductions in LDL cholesterol;
weight losses of $30 kg appeared neces-
sary to produce signiﬁcant reductions in
LDL cholesterol. A better understanding
of the factors that inﬂuence changes in
LDL cholesterol, including weight loss,
per se, caloric restriction, and dietary fat
intake, is clearly needed.
Previous studies, mostly with non-
diabetic participants, and meta-analyses
have shown that weight loss is associated
withimprovementsinotherCVDriskfac-
tors (2,7), including blood pressure (18),
triglycerides (19), and HDL cholesterol
(20). The association is typically greater
at1yearthanatlatertimepoints,asaresult
in part of weight regain (21). Thus, an
important issue is not only whether larger
weight losses produce greater improve-
mentsinCVDriskfactorsbutalsowhether
larger weight losses are more or less well
retained (22). In addition, the effects of
weight loss on CVD risk factors seem
greater initially, even if weight losses are
maintained (16,23,24). For example, in
the Swedish Obese Subjects Study (17),
gastric bypass surgery produced large
long-term weight losses, but improvements
in blood pressure seen at 1 year were no
longer signiﬁcant at year 10 (24).
In interpreting our ﬁndings, several
important limitations need to be consid-
ered. First, these analyses examined the
impact of weight loss, but change in phys-
ical activity may have been an important
independent determinant of weight loss
and/orchangesinrisk factors. Wefocused
on the weight changes, per se, in keeping
with our goal of addressing the clinical
recommendations related to weight loss.
Second, participants were not randomly
assigned to different weight loss catego-
ries; our analyses controlled for a number
of variables, including treatment group,
sex, age, and race/ethnicity, but other var-
iables may have affected success at weight
loss and/or changes in risk factors. In
addition, our analyses examined effects
at 1 year only and did not consider recent
changes in weight or the longer-term
effects. Findings for individuals with
type 2 diabetes also may not generalize
to those who do not have diabetes. Look
AHEAD is continuing to follow its par-
ticipants over time and, thus, will be able
to determine the longer-term impact
of modest weight losses on risk factors
and whether these modest weight losses
ultimately affect cardiovascular morbidity
and mortality.
Inconclusion,LookAHEADprovides
empirical support for the beneﬁts of mod-
estweightlossesat1year.However,greater
improvement in risk factors occurred with
greaterweightlosses.Becauseweightlosses
of just 5 to ,10% of initial body weight
signiﬁcantlyincreasedtheoddsofachieving
clinically meaningful changes in glycemic
control, blood pressure, HDL cholesterol,
and triglycerides at 1 year, emphasizing
modestweight losses seems tobeanappro-
priate clinical message for overweight and
obese patients with type 2 diabetes.
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